The human anti-IL-1 beta monoclonal antibody ACZ885 is effective in joint inflammation models in mice and in a proof-of-concept study in patients with rheumatoid arthritis.
about
Horror autoinflammaticus: the molecular pathophysiology of autoinflammatory disease (*)CanakinumabIL-1β at the crossroad between rheumatoid arthritis and type 2 diabetes: may we kill two birds with one stone?Disease-modifying osteoarthritis drugs: in vitro and in vivo data on the development of DMOADs under investigation.Safety and tolerability of canakinumab, an IL-1β inhibitor, in type 2 diabetes mellitus patients: a pooled analysis of three randomised double-blind studiesEfficacy and safety of the human anti-IL-1β monoclonal antibody canakinumab in rheumatoid arthritis: results of a 12-week, Phase II, dose-finding study.Immunomodulatory activity of a Chinese herbal drug Yi Shen Juan Bi in adjuvant arthritis.Caspase functions in cell death and disease.A 24-month open-label study of canakinumab in neonatal-onset multisystem inflammatory disease.The molecular mode of action and species specificity of canakinumab, a human monoclonal antibody neutralizing IL-1β.Multiparametric and semiquantitative scoring systems for the evaluation of mouse model histopathology--a systematic review.Canakinumab reduces the risk of acute gouty arthritis flares during initiation of allopurinol treatment: results of a double-blind, randomised study.Canakinumab (ACZ885, a fully human IgG1 anti-IL-1β mAb) induces sustained remission in pediatric patients with cryopyrin-associated periodic syndrome (CAPS)In-vitro validation of cytokine neutralizing antibodies by testing with ovine mononuclear splenocytes.Pharmacokinetic and pharmacodynamic properties of canakinumab, a human anti-interleukin-1β monoclonal antibodyBridging Clinical Outcomes of Canakinumab Treatment in Patients With Rheumatoid Arthritis With a Population Model of IL-1β Kinetics.Aryl hydrocarbon receptor antagonism and its role in rheumatoid arthritis.Mechanism of IL-1β modulation of intestinal epithelial barrier involves p38 kinase and activating transcription factor-2 activationAutoinflammatory Skin Disorders: The Inflammasomme in Focus.Interleukin 1 receptor antagonist mediates the beneficial effects of systemic interferon beta in mice: implications for rheumatoid arthritisIn vivo regulation of interleukin 1beta in patients with cryopyrin-associated periodic syndromesCanakinumab in patients with cryopyrin-associated periodic syndrome: an update for clinicians.NOD-like receptors and inflammation.Canakinumab for treatment of cryopyrin-associated periodic syndrome.The emerging role of interleukin-1β in autoinflammatory diseases.Cryopyrin-associated periodic syndrome: an update on diagnosis and treatment response.Difficult-to-treat gouty arthritis: a disease warranting better management.Canakinumab: in patients with cryopyrin-associated periodic syndromes.Altered bone biology in psoriatic arthritis.Emerging therapies for gout.Role of interleukin-1 inhibitors in the management of gout.Canakinumab: a guide to its use in acute gouty arthritis flares.Novel therapeutics for the treatment of familial Mediterranean fever: from colchicine to biologics.Monogenic autoinflammatory diseases.Advances in use of immunomodulatory agents--a rheumatology perspective.Role of biologics in intractable urticaria.Pharmacological treatment options for cryopyrin-associated periodic syndromes.Canakinumab for the treatment of familial Mediterranean fever.Association study of CARD8 (p.C10X) and NLRP3 (p.Q705K) variants with rheumatoid arthritis in French and Tunisian populations.BDMC33, A curcumin derivative suppresses inflammatory responses in macrophage-like cellular system: role of inhibition in NF-κB and MAPK signaling pathways.
P2860
Q24631660-2EF7F846-4DEE-4C08-9614-011EAFB89F21Q24642193-9E07590D-59CD-43AD-8E73-0934F421902FQ30251741-2529F560-C010-4032-975F-4CB43A227D60Q30588700-340A9F6B-881D-48C6-B722-18D7CFCB8FFDQ33661359-E42A74CF-0700-46FC-BCD1-409674600C97Q33953931-5DE905EB-88F8-445A-A87F-046470A7C092Q34007082-8CBF6787-48D5-4570-A14B-E76EC2F78823Q34336335-A4745F9E-C4D8-46B3-B37C-758E7EFAE94CQ34423486-E9E0DC72-3A55-4733-9220-0FC69ECEC8E8Q34489972-335E8324-5E5C-4F9C-A3AD-CC61B4C66466Q34783518-8D974E04-BA12-46D8-A9E9-429FE2033B4BQ35012174-C96F08BB-459D-483D-80D1-D19FA708B54FQ35620372-90C5A235-2B08-4154-BAE6-E22488409300Q36346817-BEFD552E-CA8E-4670-A57F-9D6FF1AB7598Q36644667-A02D3BE2-F3FA-431C-8DEB-A5FEB3FADC88Q36702456-5BC985F0-85C9-460B-B0F1-6433C566F122Q36891043-28BC2711-1323-4652-8B73-2E02D2D32C93Q36914746-16EF377D-F107-4AAB-A820-B871D10B86CBQ37048084-2C2B315D-99A1-47AA-9BF4-11EC53D07BB1Q37058559-E79D6830-17EF-45BB-BF94-F9E6B71405A5Q37273133-F388B08E-B4C2-4E33-A9AE-84CF33B9C2C2Q37331996-C3CD6BC6-9EA0-40C3-9728-C0659841E6E7Q37353179-B183EA4D-1E94-4020-B815-04CD9C860558Q37800938-ECC28D17-CC58-4106-A477-91A9A73A4DF4Q37802305-9BB997A7-20C0-4C69-BF67-67CF18BFFD74Q37811988-F2136B5B-F74F-4E36-984E-E7CA694564C7Q37910901-7DF9B24D-9379-4A26-A54E-53177EBA1680Q37968285-4AD58B40-9DEA-4F34-A398-59F7205BBDD6Q38010645-C405D7B2-9F44-4D12-96B5-3B5CE003D96DQ38057761-BC06F662-CFEE-4443-B526-596FCE9118F2Q38095844-44073A39-AAD6-445D-80B5-A8BF153240B2Q38104679-C7D11C9D-BB98-4D5D-9B92-BF48896BE4BEQ38122566-3F6613BB-E79E-4363-8BD5-245B7438513AQ38211947-F175D87D-A97B-4114-B8EF-330DA071200AQ38431512-05A57894-7525-4403-97DF-9A561C317E05Q38450662-CE8A45A3-29FB-4539-B372-EA98DDBF6298Q38674213-14AA87BA-A3C6-432A-BCC3-0B1EEF2CD8E5Q38865019-C7748D3C-6BC3-4C96-92BE-F5561725B2B4Q38902064-B755B6A6-F579-4D0E-98CF-C173670E5076Q39367047-43041D74-B024-45AB-A151-F69131CBC979
P2860
The human anti-IL-1 beta monoclonal antibody ACZ885 is effective in joint inflammation models in mice and in a proof-of-concept study in patients with rheumatoid arthritis.
description
2008 nî lūn-bûn
@nan
2008年の論文
@ja
2008年論文
@yue
2008年論文
@zh-hant
2008年論文
@zh-hk
2008年論文
@zh-mo
2008年論文
@zh-tw
2008年论文
@wuu
2008年论文
@zh
2008年论文
@zh-cn
name
The human anti-IL-1 beta monoc ...... nts with rheumatoid arthritis.
@ast
The human anti-IL-1 beta monoc ...... nts with rheumatoid arthritis.
@en
type
label
The human anti-IL-1 beta monoc ...... nts with rheumatoid arthritis.
@ast
The human anti-IL-1 beta monoc ...... nts with rheumatoid arthritis.
@en
prefLabel
The human anti-IL-1 beta monoc ...... nts with rheumatoid arthritis.
@ast
The human anti-IL-1 beta monoc ...... nts with rheumatoid arthritis.
@en
P2093
P2860
P356
P1476
The human anti-IL-1 beta monoc ...... nts with rheumatoid arthritis.
@en
P2093
Andrew M Wright
Christiane Rordorf
Gerardus J M Bruin
Gerd Burmester
Hermann Gram
Joachim Sieper
Leo A Joosten
Maria Diaz-Lorente
Piet van Riel
Rieke Alten
P2860
P2888
P356
10.1186/AR2438
P577
2008-06-05T00:00:00Z